Gene Therapy Approaches for the Prevention of Restenosis

Author(s): Christoph W. Kopp, Rainer de Martin

Journal Name: Current Vascular Pharmacology

Volume 2 , Issue 2 , 2004

Become EABM
Become Reviewer
Call for Editor


Experimental gene-therapeutic approaches for the prevention of restenosis after balloon angioplasty are the major source of our insight into pathways operative in the process of vascular renarrowing. We now understand that thrombosis and inflammation are the key mechanisms triggering vascular “healing” in response to injury and know a multitude of potential gene-therapeutic strategies to interfere with appositional thrombus formation, proliferation and migration of vascular smooth muscle cells, lesional recruitment of inflammatory cells or excess deposition of extracellular matrix. Thus far, the major limitation for clinical anti-restenotic gene therapy are concerns about the safety and efficacy of vector systems in use for the local overexpression of transgenes, which in turn is one of the most attractive advantages of gene therapy compared to systemic drug therapy. Here, we review the molecular mechanisms operative in postangioplasty restenosis by highlighting their respective gene therapeutic approaches and the current viral and non-viral vector systems.

Keywords: gene therapy, restenosis, balloon angioplasty, inflammation, smooth muscle cell proliferation, adenovirus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [183 - 189]
Pages: 7
DOI: 10.2174/1570161043476438
Price: $65

Article Metrics

PDF: 2